Hormone Replacement Therapy by Therapy (Estrogen, Human Growth, Thyroid and Testosterone Hormone Replacement Therapy), Route of Administration (Oral, Parenteral, Transdermal), Disease (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency)- and Geography

Hormone replacement treatment alludes to the treatment of the patients with development hormone insufficiency because of conditions, like, dwarfism or women approaching menopause, which requires substitution of hormones in the body whose levels have reduced. Presently, a combination of medications are utilized to treat hormone deficiencies, which are known to have better safety and efficacy parameter. Worldwide, the instances of hormone deficiency is heightening, and a large patient pool are deprived of the proper treatment. These two variables are the essential drivers of the hormone substitution treatment market.

Hormone Replacement Therapy Market Dynamics 

Several factors that are positively affecting the Hormone Replacement Therapy (HRT) market growth are growing awareness on post-menopausal issues among women, increase in drug development with novel delivery systems, and hormonal imbalance disorders with increasing ageing population. With various kinds of hormonal changes, the female body mostly gets affected by the natural process of aging, leading to abnormalities and diseases. 

Hormonal imbalance disorders, including menopause, are the key factors driving the market for hormone replacement therapy. The female body undergoes several types of hormonal changes. Hormone levels get altered with growing age, leading to various disorders and diseases. Moreover, increase in cases of endocrine diseases across the globe and increasing health awareness coupled with  strong pipeline is expected to drive the hormone replacement therapy market. On the down side,  hormone replacement therapy is majorly hampered by scarcity of experts coupled with high treatment cost.

Hormone Replacement Therapy Market Segmental Highlights

The report analyses the global hormone replacement therapy market based therapy, route of administration, disease and geography

• The various types of hormone replacement therapy are categorised into estrogen, human growth, thyroid and testosterone replacement therapy. The estrogen hormone replacement therapy is likely to observe the largest number of prescriptions as this therapy is used in women during post-menopause or hysterectomy and helps them maintain the hormonal balance. 
• Moreover, the hormone growth replacement therapy is likely to observe significant growth owing to the rising incidences of growth deficiencies, particularly in infants. According to WHO, an estimated 15 million babies are born preterm and this number is rising and approximately 85% of these infants are not fully developed. Thus, the demand of the HRT is increasing.
• The hormone replacement therapy can be administrated through various routes such as oral, parenteral, and transdermal. Oral medication is the most common form of hormone replacement therapy. Examples are conjugated Estrogens (Premarin), estradiol (Estrace), and Estratab.
• The hormone replacement therapy is used to treat various diseases such as menopause, hypothyroidism, male hypogonadism, growth hormone deficiency etc. The menopause segment is likely to account for the largest market share. Rapidly increasing population of geriatric women leads to increase in the number of women with menopausal symptoms. According to the WHO statistics of 2015, the global sex ration is nearly 101.7, it is an indication that the number of women are increasing, globally. The global population is anticipated to reach 7.7 Bn by the end of year 2020 out of which nearly around 8% will comprise of women with age group between 40to60 years, therefore there lies a huge market opportunity for companies engaged in providing vasomotor symptoms treatment caused due to menopause..
• Based on geography, the global Hormone Replacement Therapy market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America accounted for the largest market share owing to the growing baby boomer population, high health care expenditure, and large number of prescriptions of hormonal treatment products.
• North America region accounted for largest market share  holds the major market share for hormone replacement therapy market throughout the coming years. 
• Asia-Pacific emerged as the fast growing regional segment in terms of revenue due to the increase’s cases of cardiovascular diseases and rapidly aging population.

Key players in the global hormone replacement therapy market include Abbott Laboratories, Novartis AG, Pfizer Inc., Mylan Laboratories, Merck & Co., Novo Nordisk AS, Bayer AG, Eli Lilly and Company, Genentech, F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co. Inc., Allergan, Noven Pharmaceuticals, Orion Pharma, Therapeutics MD, Endo Pharmaceuticals Inc, and Teva Pharmaceutical Industries Ltd among others.

Hormone Replacement Therapy Key Developments 

July 2018: Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Vagifem®1 (estradiol vaginal inserts), 10 mcg in the U.S.

February 2015:  Mylan Laboratories acquired of Famy Care for USD 750 million in February 2015. Post the acquisition, Mylan undertook the female health business inclusive of the production of hormone replacement drugs, contraceptives, and Intra-Uterine Devices (IUD).